Newsletter

July 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 5 Percent Correct – Prev Close to 5-day Peak 80% Avg Increase – Next open to 5-day Peak 17% Other stats: Number of signals over $10/share 3 Number […]

0Comments

FDA Transfers BIVIGAM and Nabi-HB Licenses to ADMA Biologics

On July 8, ADMA Biologics, Inc. (ADMA) reported that they now hold the licenses for BIVIGAM and Nabi-HB that previously belonged to Biotest Pharamceuticals. This was the final regulatory item outstanding from ADMA’s acquisition of the Biotest Therapy Business Unit in June 2017. The FDA had to revoke the license from Biotest Pharmaceuticals and perform […]

0Comments

June 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 15 Percent Correct – Prev Close to 5-day Peak 21% Avg Increase – Next open to 5-day Peak 19% Other stats: Number of signals over $10/share 13 Number […]

0Comments

Krystal Biotech Reports Positive News from Phase 2 Clinical Trial of KB103

On June 24, Krystal Biotech (KRYS) reported positive news from its Phase 2 clinical trial of KB103. The treatment was effective and well tolerated by patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). In addition, the FDA awarded Regenerative Medicine Advanced Therapy (RMAT) status to Krystal Biotech for KB103. Krystal Biotech is a gene therapy […]

0Comments

Ziopharm Receives FDA Clearance for IND with the National Cancer Institute

Ziopharm Oncology (ZIOP) announced on June 11 that the FDA approved an investigational new drug (IND) application as part of a research and development project the company has with the National Cancer Institute. They will now begin clinical trials in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy that uses Ziopharm’s Sleeping Beauty platform. […]

0Comments

May 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 6 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 3 Number […]

0Comments

La Jolla Pharmaceutical Announces Positive Phase 2 Results of LJPC-401

On June 6, La Jolla Pharmaceutical Company (LJPC) announced positive clinical trial results from its Phase 2 study of LJPC-401. This was a pre-specified interim analysis of its synthetic human hepcidin in patients with hereditary hemochromatosis (HH). Patients experienced statistically significant efficacy levels and tolerated the drug well.   Rocket Tickers detected the news event […]

0Comments

April 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 4 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 100% Other stats: Number of signals over $10/share 2 Number […]

0Comments

March 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 15 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 10% Other stats: Number of signals over $10/share 8 Number […]

0Comments

Lannett Receives FDA Approval for Aspirin and Extended-Release Dipyridamole Capsules

On March 27, Lannett Company, Inc. (LCI) reported that they have received FDA approval for their Abbreviated New Drug Application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200mg. The drug is the therapeutic equivalent to Aggrenox Capsules, 25 mg/200 mg by Boehringer Ingelheim Pharmaceuticals. Total annual sales in the US for Aspirin and Extended-Release Dipyridamole […]

0Comments